In NACC data, individuals taking MGAM-inhibiting drugs (acarbose and miglitol) showed slower clinical dementia rating progression (<i>p</i> < 0.01) in comparison with the non-taking group.<h4>Discussion</h4>This study is the first to report a genetic association between TAS2R38 and AD biomarkers. This evidence concerns the gene TAS2R38 and Alzheimer disease.